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Gadolinium-based contrast agents (GBCAs) enhance the tissue visualization allowing 
to the doctor differentiate between abnormal tissues and normal tissues in a patient 
by using magnetic resonance imaging (MRI). Among all commercialised agents, the 
mixed contrast agent Primovist or, chemically known as Gadoxetate Disodium, has 
a great interest in application in MRI studies. This fact can be explained due to its 
ability to have dual excretion pathway which allow the detection of the vascular and 
hepatic injuries in one single injection. For this reason, this review will be focused on 
the synthetic route toward Primovist to find out a better pathway for this 
pharmacological product in terms of yield, purity and suitability to operate at 
industrial scale.  
RESUMEN 
Los agentes de contraste basados en gadolinio (GBCA) mejoran la visualización de los 
tejidos, facilitando a los médicos llevar a cabo una buena diferenciación entre los 
tejidos patológicos y los tejidos normales de un paciente mediante resonancia 
magnética nuclear de imagen (RMI). Entre todos, los agentes de contraste mixtos 
como Primovist, conocido como Gadoxetato Disódico, han tenido un gran interés 
de aplicación en los estudios de resonancia magnética nuclear por imagen. Este 
hecho se puede explicar debido a que presentan como característica principal la de 
poseer una vía de excreción dual, permitiendo la detección de lesiones vasculares y 
hepáticas en una sola inyección. Por esta razón, en esta revisión bibliográfica se 
prestará mucha atención en la única ruta sintética descrita para la obtención de 
Primovist, con el fin de encontrar una mejor ruta para este producto farmacológico 
en términos de rendimiento, pureza e idoneidad para operar a nivel industrial. 
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1.1. Magnetic Resonance Imaging (MRI) 
Magnetic Resonance Imaging (MRI) was invented by Paul C. Lauterbur in 1971 
and it is powerful technique for application in diagnostic clinical medicine and in 
biomedical research. This technique can transform spatial information of the water 
molecules present in tissues into an NMR signal using magnetic field gradients. After 
years gaining insight into this field, the first clinical full body MRI machine (Figure 1) was 
not installed until 1980 and since that time, essential improvements have been made, 
leading to its widespread use in medicine today.  
Figure 1. First MRI scanner build in 1980. 
Magnetic Resonance Imaging [1] (MRI), unlike conventional 
radiography and computed tomographic (CT) which employ 
potentially harmful (X-ray) radiation, is known as a harmless 
and non-invasive imaging technology that produces detailed 
three-dimensional anatomical images of biological tissues 
used in radiology. So, MRI is an essential technique which is 
useful for doctors in the early detection, diagnosis, and 
treatment monitoring of human disease. Therefore, it can be 
summarized as an elaborate proton nuclear magnetic 
resonance (NMR) that visualizes the magnetic properties from tissue water protons, 
whose concentration in our body is around 35 M. Before explaining the mainly 
applications and the evolution of MRI, it is crucial to understand a little bit about the 
physics phenomena behind MRI consists of, by explaining the experimental procedure 
of an MRI in a real situation. 
During an MRI procedure, a patient is placed inside a cylindric magnet, called MRI 
scanner, and it must remain restful until the imaging process is finished so as not to get 
blurred images. MRI scanners [2] make use of powerful magnets which lead to a strong 
magnetic field that drive water protons inside the body to align with that field. 
 
[1] De Leõn-Rodríguez, L. M.; Martins, A. F.; Pinho, M. C.; Rofsky, N. M.; Sherry, A. D. Basic MR relaxation 
mechanisms and contrast agent design. J. Magn. Reson. Imaging 2015, 42 (3), 545-565. 
[2] Chimie, L. D. E.; Et, I. Highly Efficient MRI Contrast Agents:  from Monomers to Nanoparticles. Thesis, 
École Polytechnique Fédérale De Lausanne, December 2008.  
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Subsequently, an intense radiofrequency pulse, known as Larmor frequency, is then 
applied through the patient that tips the net magnetization vectors generated by the 
hydrogen nuclei in the direction of the receiver coil.  Once the radiofrequency field is 
switched off, the MRI sensors are able to detect the energy released as the protons bring 
the net magnetization vectors back (only longitudinal component or T1 and without 
transverse component or T2) to its equilibrium position in alignment with the initial 
applied magnetic field. This magnitude signal in energetic terms detected by the receiver 
is used to form the MR image with the aid of computer software. Moreover, this signal 
is related to the time it takes for the protons to realign with the magnetic field, known 
as the T1 or T2 relaxation time and changes depending on the environment and the 
chemical nature of the water molecules present in soft tissues. As I have just mentioned, 
water protons in tissue are characterised by these two relaxation times constants, T1 
and T2, which both affect the images’ signal intensity. By consensus, T1 (or also called 
longitudinal relaxation time) is defined as the time it takes for 63% of its longitudinal 
magnetization component to recover, while T2 of a tissue is defined as the time it takes 
to lose 63% of its total transverse magnetization signal. With this useful data in hand 
provided by MRI machine, doctors have been able to detect if there is a disease process 
or injury present inside the patient. So, the key of this technique for ensuring an 
appropriate image and being able to differentiate abnormal and normal tissues are both 
relaxation times T1 and T2, but as we are going to see later in case of gadolinium agents 
the effect is higher on T1-weighted images. MRI in humans is extensively used today 
thanks to Raymon Damadian et al. [3] who discovered in the 1970's that the T1 of tumours 
(Table 1)[3] in animals were significantly longer than T1 values of the corresponding 
normal tissues.  This outcome led to an extension of the study in humans to differentiate 
as much as possible abnormalities in our tissues.  
Table 1. T1 relaxation times in normal and malignant tissues. 
Tissue T1 tumour (s) T1 normal (s) 
Bone 1.027 0.554 
Breast 1.080 0.367 
Liver 0.832 0.570 
Lung 1.110 0.788 
Skin 1.047 0.616 
 
 
[3] Damadian, R.; Zaner, K.; Hor, D.; DiMaio, T. Human tumors detected by nuclear magnetic resonance. 
Proc. Natl. Acad. Sci. U. S. A. 1974, 71 (4), 1471-1473. 
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Due to the difference between the abnormal and normal tissues relaxation times 
together with the differences observed in their signal intensities, the medical doctors 
can determine or detect a possible case of an early tumour stage. Regarding the duration 
of an MRI examination, it can be said that it is quite long most of the cases and 
particularly the contrast between healthy and unhealthy tissues might be not enough to 
ensure the detection of a certain disease. For this reason, a class of pharmacological 
products, called MRI contrast agents [4,5,6] have been used years ago for improving the 
visualization of these tissues. 
1.2. Contrast Agents 
Despite the great advances in MRI, there are still some kind of pathologies that 
cannot be fully assessed by MRI. For this reason, the appealing for chemical agents, 
known as contrast agents, can be a useful tool to overcome the main weaknesses of 
MRI itself. These kinds of compounds provide detailed analysis and anatomic depiction 
of the vascular system as well as they help to improve the visibility in certain tissues 
making these pharmacological products widely used in diagnostic imaging for nearly 30 
years. Just after the introduction of MRI technique, the first contrast agent developed 
in human study was reported in 1981[7], using oral ferric chloride for gastrointestinal (GI) 
tract. Since that time, many other contrast agents [8] have been launched to the market 
differing in their magnetic properties, chemical composition, biodistribution, imaging 
applications and its administration route.  
Up to date, MRI contrast agents may be divided into different two groups. The first group 
comprises paramagnetic compounds, like lanthanides elements such as gadolinium, 
whereas the second group is composed by transition elements such as manganese and 
 
[4] Carrasco Muñoz, S.; Calles Blanco, C.; Marcin, J.; Fernández Álvarez, C.; Lafuente Martínez, J. 
Contrastes basados en gadolinio utilizados en resonancia magnética. Radiologia. 2014, 56 (S1), 21-28. 
[5] Choi, Y.; Huh, J.; Woo, D. C.; Kim, K. W. Use of gadoxetate disodium for functional MRI based on its 
unique molecular mechanism. Br. J. Radiol. 2016, 89 (1058), 1-9. 
[6] Le Fur, M.; Caravan, P. The biological fate of gadolinium-based MRI contrast agents: a call to action for 
bioinorganic chemists. Metallomics 2019, 11 (2), 240-254. 
[7] Young, I. R.; Clarke, G. J.; Baffles, D. R.; Pennock, J. M.; Doyle, F. H.; Bydder, G. M. Enhancement of 
relaxation rate with paramagnetic contrast agents in NMR imaging. J. Comput. Tomogr. 1981, 5 (6), 543-
547. 
[8] Lohrke, J.; Frenzel, T.; Endrikat, J.; Alves, F. C.; Grist, T. M.; Law, M.; Lee, J. M.; Leiner, T.; Li, K. C.; 
Nikolaou, K.; et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future 
Perspectives. Adv. Ther. 2016, 33 (1), 1-28. 
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iron (also known as superparamagnetic contrast agents). The available contrast agents 
possess a similar mechanism of action, consisting in accelerate the relaxation rates of 
the surrounding protons (longitudinal (T1) and transverse (T2) relaxation times), allowing 
a reduction in the examination time and improving the accuracy of imaging contrast. 
The gadolinium-based chelates have represented the mainstay of intravenous contrast-
enhanced MR imaging since their introduction into clinical use of Gadopentetate  
Dimeglumine (Gd-DTPA) in 1998[9]. Since that time, several Gd chelates have been 
developed to improve clinical efficacy and patient safety.  
Gadolinium Based Contrast Agents  
Gadolinium Based Contrast Agents (GBCA) can be divided in function of their 
administration route. Thus, they can be found as intravenous, oral or ventilation 
contrast agents (Figure 2), being all of them using for MRI. For example, oral MRI agents 
are primarily used to produce detailed images of the small intestine, enterography. 
However, the ventilation contrast agents are suitable for lung examination: the 
intravenous contract agents are useful to enhance the visibility of the vascular system 
and structures and some specific tissues. So, their use can be tailored to a specific 
disease.     
                                                                                     Figure 2. Route of administration of MRI contrast agents. 
But now, intravenous contrast 
agents are by far the most 
predominant in clinical practice  
since their huge scope of 
application. Regarding the 
mechanism of action, intravenous 
gadolinium contrast agents modify 
the T1 relaxation time in most 
cases, whereas iron contrast agents work through T2 effect. Another fact, that explain 
the huge use of gadolinium complexes is about the adverse effects which tend to be 
mild in comparison to other metal complexes.  
 
[9] Pierre, V. C.; Allen, M. J.; Caravan, P. Contrast agents for MRI: 30+ years and where are we going? 
Topical issue on metal-based MRI contrast agents. Guest editor: Valérie C. Pierre. J. Biol. Inorg. Chem. 
2014, 19 (2), 127-131. 
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Therefore, the most commonly used contrasts currently are those based on Gadolinium 
(Gd), although there are also contrast media for other elements, such as Mn 
(Mangafodipir trisodium marketed under the name Teslascan) and Fe (Super 
Paramagnetic Iron Oxide nanoparticles, Sinerem), but they are currently in disuse since 
that none have presented at large scale as well as their poor clinical performance and 
concerns over toxicity issues.  
Based on their chemical structure, GBCA are molecules which contain two different 
moieties. The first one is composed by lanthanide rare metal (in this case gadolinium) 
and the second one tends to be an organic ligand such as polyamino-polycarboxylic 
derivatives which are able to reduce the toxicity generate by the presence of the free 
ionic form. 
                                                                              
Considering that the stability of these 
kind of compounds is important since 
body fluids contain a large number of 
ligands or endogenous metal ions. So, 
various competitive reactions can 
occur in vivo. For instance, 
endogenous cations like Fe3+, Ca2+, 
Zn2+, Cu2+ can react with gadolinium 
chelates by displacing Gd+3 in a process known as transmetallation exchange. Between 
the endogenous ions located in blood pool, only zinc (Figure 3) can displace significant 
amount of Gd3+ due to its high concentration in the blood (55–125 mol/L). Due to the 
low copper concentration (1–10 mol/L) and the low calcium affinity to organic ligands, 
these two metals have not influence on the transmetallation exchange. Moreover, iron 
ions are tightly bound to the storage proteins ferritin and haemosiderin and are not 
available for transmetallation with Gd3+. As a result, zinc ions are the best competitors 
for gadolinium species. On the other hand, free Gd+3 can be complexed by binding 
proteins, endogenous ions (citrate) or endogenous anionic precipitants (CO32-, OH-,  
PO43-), so the chelation is essential to minimize the risk of deposition of free gadolinium 
in certain organs to prevent the onset of some diseases like nephrogenic systemic 
Figure 3. A diagram of the process of transmetallation 
between Gd3+ and endogenous cations such as zinc (Zn2+).  
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fibrosis (NSF).[10] Focused on their molecular structure, the main GBCA used may be 
divided into macrocyclic and linear agents (see Table 2 and Figure 4). 
Table 2. List of approved Gd MRI contrast agents. 





















































25.4 Extracellular Kidney 
*In November 2017, the European Commission [11] adopted the decision of the European Medicines 
Agency to suspend the marketing authorizations for intravenous use like Omniscan, Optimark, 
Ablavar and Magnevist and to restrict the use of MultiHance to liver scans only. 
In macrocyclic compounds, the gadolinium ion is captured in a molecular cavity within 
the chelating agent being more stable than linear compounds, allowing a lower rate of 
dissociation of free gadolinium ion and much less adverse effects for these complexes 
(see values in Table 2). For instance, Dotarem possesses a higher value of LogKterm in 
comparison with other contrast agents. By contrast, linear agents can be subdivided into 
ionic and nonionic compounds. It is essential for the use of these compounds their 
stability parameters since the availability of free gadolinium has been related with the 
pathogenesis of NFS among other diseases, for example using Omniscan as a nonionic 
linear GBCA. 
 
[10] Weller, A.; Barber, J. L.; Olsen, Ø. E. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr. 
Nephrol. 2014, 29 (10), 1927-1937. 
[11] Medicines Agency, E. https://www.ema.europa.eu/en/news/emas-final-opinion-confirms-
restrictions-use-linear-gadolinium-agents-body-scans (accessed April 23, 2020). 
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The less adverse effects on these agents are due to the dosage. While in radiographic 
and computed tomography (CT) what you see and analyse is directly the iodine 
molecule, by contraposition in MRI what is analysed after its administration is the effect 
of the paramagnetic metal on the adjacent water protons. This mean that a single Gd 
atom modifies the relaxation times of many water protons. This fact can be seen 
reflected in dosage, which is an important feature in general medication, since the 
lowest possible dose of any drug prevent from suffering the onset of certain diseases. A 
great advantage of GBCAs in front of iodine-based contrast agents used in CT is that a 
single molecule of GBCA can affect many surrounding waters protons. The standard 
administration dose is 0.1 mmol/Kg of weight, equivalent to 0.2 ml/Kg in case of 
gadolinium agents. However, with iodine contrast agents though have a different 
mechanism of action it is needed more amount of CA to observe a certain contrast. It is 
said “The more iodine, the denser the X-ray effect”, so we need much amount of iodine 
CA to have a similar contrast like GBCA. As a result, a much lower dose of GBCA is 
required compared to iodine CAs to achieve a similar degree of contrast enhanceme nt. 
Regarding to the mechanism of action of GBCAs, it is said that gadolinium agents possess 
a pronounced effect through the T1 relaxation times. Previous studies [12] confirmed that 
water T2 is generally 5-20 times shorter than T1. As a result, the effect of a Gd (III) 
contrast agent will be much more pronounced on T1 but it should not be ruled out in 
some pathologies T2 can be predominant as well.  
 
[12] Wahsner, J.; Gale, E. M.; Rodríguez-Rodríguez, A.; Caravan, P. Chemistry of MRI contrast agents: 
Current challenges and new frontiers. Chem. Rev. 2019, 119 (2), 957-1057. 
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Going into a brief detail in his mechanism, gadolinium complexes preferentially induce 
T1 relaxation in tissues where they accumulate. Focusing on Gd features, this metal 
exhibits powerful paramagnetic behaviour since possess 7 unpaired electrons in its 4f 
shell. Previous experiments confirmed that these inner electrons are not involved with 
bonding and this evidence concluded that Gd complexes possessed the same 
paramagnetic whether is free or attached to organic ligands. Moreover, most Gd 
contrast agents commercially available have nine coordination sites for bonding and 
chemical interactions. In most cases, the ligand group complexes to Gd3+, which 
occupies eight of these sites while the last site is available for interacting with water as 
one can see depicted in Figure 5.[13] 







*The Gd+3 ion is coordinated with 5 oxygen atoms (blue) and 3 nitrogen atoms (red). Structural carbon 
atoms are black. The crevice in the molecule leaves room for a single water molecule (blue and green) to 
interact directly with the Gd+3 ion (inner sphere relaxation). Beyond this a second shell of other water 
molecules experience outer sphere relaxation. 
 
Figure 6. Enhanced contrast imaging after Gadolinium injection. 
In a nutshell, dipolar interactions between water 
nuclei and unpaired electrons of the metallic 
center are taken placed and known as 
paramagnetic relaxation enhancement (PRE). As a 
result, this led to improve the contrast in some 
tumours (Figure 6). After briefly explaining how T1 is induced by contrast agents we 
should know that in speaking terms MRI contrast agents are characterized by its 
relaxivity value (r), which is defined as the paramagnetic enhancement of the 
 
[13] Paramagnetic relaxation - Questions and Answers in MRI http://mriquestions.com/paramagnetic-
relaxation.html (accessed abr 23, 2020). 
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longitudinal relaxation rate of water protons (T1 and T2) in presence of 1 mM 
paramagnetic ion concentration.  
This value reflects how the relaxation rates of T1 and T2 changes as a function of 
concentration as shown in equations below.     
      
Since ΔT1 and ΔT2 are given in seconds and [C] in milimoles per liter, r1 and r2 have units 
of L/mmol-s. Considering this parameter, some contrast agents clinically approved have 
certain variability among r1 and r2 values. Agents with larger relaxivities (r1 and r2) are 
those with higher molecular weights, higher protein binding like Eovist, which provide 
a brighter image on T1-weighted (see Table 3). Eovist is the CA that possess a greater 
relaxivity value (without taking into consideration Ablavar which is a blood pool agent 
and possess the high protein binding) which determines how bright the contrast agent 
appears on T1-weighted MRI. This fact makes Eovist optimal for detecting 
enhancement on T1 and T2 weighted images at standard doses.  
Table 3. r1 and r2 relaxivities for marketed GBCA obtained in plasma at 37ºC at 1.5T. [14] 
According to their pharmacokinetics properties, Figure 7 shows the distribution and 
excretion pathways for GBCAs. An intravenous agent rapidly equilibrates between 
intravascular and interstitial fluid compartments (known as extracellular compartment).  
After that depending on its structure, the complex might also be distributed into 
intracellular environments (such as liver) by passive diffusion or specific uptake 
processes or excreted directly through the kidney.  
 
[14] Hao, D.; Ai, T.; Goerner, F.; Hu, X.; Runge, V. M.; Tweedle, M. MRI contrast agents: Basic chemistry 
and safety. J. Magn. Reson. Imaging. 2012, 36 (5), 1060-1071. 
Brand Name T1 relaxivity (r1) T2 relaxivity (r2) 
Magnevist 3.9 – 4.3 3.8 – 5.4 
MultiHance 6.0 – 6.6 7.8 – 9.6 
Primovist/Eovist 6.5 – 7.3 7.8 – 9.6 
Vasovist/Ablavar 18.0 – 20.0 32.0 – 36.0 
Omniscan 4.0 – 4.6 4.2 – 6.2 
OpmiMARK 4.4 – 5.0 4.3 – 6.1 
Dotarem 3.4 – 3.8 3.4 – 5.2 
ProHance 3.9 – 4.3 4.2 – 5.8 
Gadovist 4.9 – 5.5 5.2 – 7.0 
Equation 1. Relaxivity expression. 
1/ΔT1 = r1 • [C]           and         1/ΔT2 = r2 • [C] 
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According to its biodistribution GBCA may be categorized in 3 types: (a) extracellular 
agents (ECAs), (b) blood pool agents and (c) target/organ-specific agents.  
Extracellular agents (ECAs) were the 
first to be introduced into clinical practice. [15] 
They are hydrophilic and typically small 
molecular weight (around 500 daltons) 
compounds with nonspecific distribution. They 
are consisting of a chelating agent that tightly 
encapsulates the gadolinium ligand, preventing 
its cellular uptake. After intravenous 
administration, GBCA are quickly and freely 
equilibrate between the extracellular 
compartments (interstitial and intravascular spaces), and then they are excreted 
exclusively through the kidneys with a plasma half-life of 1.5 hours in patients with 
normal renal function. By contrast, in patients with renal impairment an increase in 
plasma half-life of gadolinium compounds is noticed and depending on renal function it 
can varies from 7-8 hours to days.   
Blood Pool Agents are compounds used mostly in magnetic resonance 
angiography (MRA). After their injection they are distributed exclusively in the 
intravascular space due to their reversible binding to albumin, providing a high contrast 
for imaging in arteries and veins. Due to the high capacity to bind (80-90%) to albumin 
protein, blood pool agents have longer intravascular half-live than ECA. The most 
important of the low-molecular-weight agents is Gadofosveset trisodium (Ablavar), a 
monomer which noncovalently binds to albumin (80-90%) in human plasma, making it a 
blood pool agent. The remain fraction unbound is then eliminated through the kidneys, 
but now is no longer in use since the main drawback of this agent is the risk of 
gadolinium dissociation related to their prolonged retention in the body.  
 
 
[15] Aime, S.; Caravan, P. Biodistribution of gadolinium-based contrast agents, including gadolinium 
deposition. J. Magn. Reson. Imaging 2009, 30 (6), 1259-1267. 
Figure 7. Main distribution sites and excretion 
pathways for intravenously administered 
soluble metal complexes. 
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Hepatobiliary Agents or also known as mixed contrast agents were developed to 
detect the diagnosis of focal hepatic lesions, and include Gadobenate Dimeglumine (Gd-
BOPTA, MultiHance) and Gadoxetic acid (Gd-EOB-DTPA, Eovist, Primovist). These 
agents are taken up by hepatocytes through an active transport mechanism and are  
cleared intact via the hepatobiliary system. Thanks to their cellular liver uptake, these 
agents can therefore be used to image the liver and biliary system. Both agents in the 
first few minutes after their administration act as a conventional ECAs and after 20 min 
or more (60-120 min in case of MultiHance), an enhancement of liver parenchyma is 
taken place in order to stand out hepatic lesions as dark spots. The degree of hepatic 
clearance varies from 2% (Gadobenate dimeglumine [Multihance]) to 50% (Gadoxetate 
disodium [Eovist]) depending on the agent, making Eovist the most useful liver 
contrast enhancement.  
1.3. Gadoxetate disodium, Primovist 
Gadolinium ethoxybenzyl dimetilglumine (Gd-
EOB-DTPA, sold as Primovist in Europe and 
Evoist in USA) is a liver-specific MRI contrast 
agent manufactured by Bayer HealthCare 
designed for liver imaging. The chemical 
structure of the complex closely seems to Gd-
DTPA, but with one arm of the ligand containing 
a highly lipophilic ethoxybenzyl (EOB) group 
responsible for the liver uptake. [16] 
This agent is useful since it has up to 50% 
hepatobiliary excretion in the normal liver followed by 50% renal excretion. After 
intravenous injection, Primovist initially distributes into the vascular and extracellular 
spaces in a similar way to non-specific gadolinium agents. Afterwards, a half of the 
administered dose progressively accumulates into hepatocytes cells and then is 
excreted into the biliary tract. Subsequently, the remainder dose is excreted renally by 
the kidneys through glomerular filtration. Overall, unlike other agents, Eovist has 
 
[16] Van Beers, B. E.; Pastor, C. M.; Hussain, H. K. Primovist, eovist: What to expect? J. Hepatol. 2012, 57 
(2), 421-429. 
Figure 8. Cellular pharmacology of Gd-
EOB-DTPA.  
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double distribution and elimination pathways allowing it to be used to assess both 
vascularity and function of liver lesions. The resulting hepatic enhancement in the liver 
is achieved by the transport through OATP1B1/B3 (Organic Anion Transporting 
Polypeptide) and MRP2 (Multi Drug Resistance Protein) transporters located in the 
sinusoidal and canalicular membrane (Figure 8) respectively. Several human and animal 
studies [17] have shown that the detection of nonhepatocellular tumors can be improved 
much more by the administration of Gadoxetate Disodium or Gadobenate Dimeglumine. 
This fact can be explained by the selective uptake of hepatobiliary contrast agents in 
functional hepatocytes and the lack of uptake in tumors generating a substantial 
contrast. For these benefits, this review will pay much attention on the synthesis of 
Gadoxetate Disodium in order to seek a new synthetic route suitable and practical to be 
transferred at commercial scale. 
1.4. Synthetic Route Towards Gadoxetate Disodium 
 The design of octadentate ligands derivatives such as 
diethylenetriaminepentaacetato (DTPA) is still a current challenge at large scale for the 
synthesis of contrast agents. Its importance is due to the need for a high thermodynamic 
stability complex in order to prevent the release of free Gd(III) into the body’s patient. 
Many approaches have been done in literature [18] to achieve the synthesis of a large 
variety of chelators used to the formation of desired complex.   
 Years before, around 1996-98 two patents (US5798092 and US5482700)[19, 20] 
were published regarding the synthesis of Primovist. Unfortunately, both presented 
some drawbacks at the time to transferring at large scale owing to the use of expensive 
and complex reagents such as diborane compounds. Apart from that, some procedures 
were undesired at industrial scale such as chromatographic purification which is usually 
avoided. But not until 2017, a patent was filed to the synthesis of Gadoxetate at level 
 
[17] Müller, A.; Clément, O.; Vexler, V. Hepatobiliary Enhancement with Gd-EOB-DTPA: Comparison of 
Spin-Echo and STIR Imaging for Detection of Experimental Liver Metastases. Radiology.1998, 184, 207-
213. 
[18] Frullano, L.; Caravan, P. Strategies for the Preparation of Bifunctional Gadolinium(III) Chelators. Curr. 
Org. Synth. 2011, 8 (4), 535-565 
[19] Deutsch, J.; Gries, H. Substituted polyamino, polycarboxy complexing agent dimers for MRI and X-Ray 
contrast. U.S Patent 5,482,700, Jan 9, 1996. 
[20] Schmitt-Willich, H.; Platzek, J. Derivatized DTPA complexes pharmaceutical agents containing these 
compounds, their use, and processes for their production. U.S Patent 5,798,092, Aug 25, 1998. 
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scale with slightly improvements.[21] It is based on a multi-step synthesis with at least 
nine steps, from the commercially available L-tyrosine 1 as depicted in Scheme 1.  
The first synthetic step involves the protection of amino group of L-tyrsoine 1 
with di-tert-butyl dicarbonate (Boc2O) in presence of base. The resulting compound 2 
was alkylated in phenol position with diethyl sulphate (Et2SO4) in a basic medium 
affording the derivative 3. The remain carboxylic acid present in 3 was activated by 
undergoing the reaction in presence of ethyl chloroformate (ECF) or methyl iodide in 
order to generate in situ the corresponding anhydride or methyl ester, which is then 
reduced in a slightly conditions by using sodium borohydride  (NaBH4) resulting the 
hydroxy derivative 4. The obtained alcohol 4 was activated with methane sulfonyl 
chloride (MsCl) in presence of triethylamine (Et3N), as a base, providing de mesyl 
derivative 5. The subsequently condensation of this intermediate with ethylenediamine 
along with the deprotection of Boc group resulted in the chiral triamine intermediate 7. 
Then, the alkylation reaction of chiral triamine to get the pentacarboxilic derivative 8 
was conducted using two different strategies. The first one involves two steps, in which 
firstly took placed the alkylation of triamine using tert-butyl bromoacetate affording the 
intermediate 7a. Then, it was hydrolysed in basic medium to provide pentaacetylated 
derivative 8. The second strategy involves a direct alkylation process using chloroacetic 
acid, providing directly the pentaacetylated derivative 8 with a 42% yield after a 
purification process. At last, the complexation of EOB-DTPA with Gd+3 was conducted by 
adding gadolinium oxide (Gd2O3) to the ligand in water at 80ºC for 1h. The final 
compound 9 was isolated after a purification process. 
 
[21] Pullagurla, M. R.; Pitta, B. R. Novel process for the preparation of Gadolinium complex of (4S)-4-(4-
ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9 triazaundecanedioic acid disodium (Gadoxetate 
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 As it was mentioned before, two hepatobiliary GBCA, Gadobenate Dimeglumine 
and Gadoxetate Disodium, which are still in use were discovered to this date. Unlike 
Gadobenate dimeglumine, Gadoxetate has the advantage of being faster offering 
abnormalities results in liver around 20 minutes in comparison to nearly 1 hour, in case 
of Gadobenate. For this reason, this review will be focused on a deeply way in the 
synthesis of Primovist. 
 Currently, the production procedure belongs to Bayer which raise the price of 10 
mL up to 182 Euros. For this reason, one of the current challenges into the 
industrialization of specific pharmacological products is to provide an economically 
efficient synthesis with high yields and purities to fulfil with the safety’s specifications.  
 Thus, based on the recent synthetic pathway of Scheme 1 reported in the 
mentioned patent WO2017208258A1, the aim of this work is to make an exhaustive 
bibliographic research into the synthetic pathways of Primovist and its intermediates, 
in order to seek new alternatives. These new synthetic procedures will result in an 
enhancement of the process at level scale, from its overall yield and purity to reduce the 
use of undesired reagents and improve its reproducibility.




3. RESULTS AND DISCUSSION 
3.1. Synthesis of L-protected tyrosine  
 The first step in the synthesis involves the amino protection of L-tyrosine (1) as 
it was shown in the Scheme 1. According to bibliographic search, the protection of 1 can 
be carried out by using di-tert-butyl carbonate (Boc2O) or benzyl chloroformate (Cbz-Cl) 
affording the tert-butyl (2a) or benzyl carbamate (2b) derivatives (Scheme 2).  
Scheme 2. L-Tyrosine amine protection. 
1 2a = X (Boc)
2b = X (Cbz)  
As it is shown in the Table 4 (entries 1&2), the formation of Boc protected L-tyrosine 
(2a) can be conducted under either an aqueous base (NaOH) or organic base (Et3N) 
obtaining similar and good yields. By contrast, slightly better yields are obtained when 
Cbz is used as a protecting group (Table 4, entries 3&4). In this case, aqueous bases are 
the common conditions for taking place the subsequent formation. The key difference 
between these two protecting groups, is really in how they are removed as we will see 
in later steps, making Cbz a better protecting group for this synthetic process owing to 













Table 4. Synthetic conditions for the synthesis of L-amino protected tyrosine. 
 
3.2. O-Alkylation of protected L -tyrosine 
The second step of the process consist on the O-alkylation of Boc or Cbz 
protected L-Tyrosine derivatives. In a first instance[21] (see Scheme 3), it was conducted 
under basic aqueous conditions (4M NaOH) in presence of diethyl sulphate (Et2SO4) as 
alkylating agent to get (S)-2-((tert-butoxy carbonyl) amino)-3-(4-
hydroxyphenyl)propanoic acid (3a) in a 78% yield (see entry 1, Table 5).  





These conditions in terms of environmentally speaking are the most suitable for 
this process since neither solvents nor organic reagents are used in that methodology. 
O. Nyéki et al. [25] performed the same reaction with similar conditions obtaining a better 
yield, 94% in 24 hours. (see entry 2, Table 5). This was accomplished by changing the 
manipulation of the experimental procedure. In entry 1, once the reaction is finished, 
 
[22] Zhang, Y.; Feng, J.; Liu, C.; Fang, H.; Xu, W. Design, synthesis and biological evaluation of tyrosine-
based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. Bioorganic Med. Chem. 
2011, 19 (15), 4437-4444. 
[23] Dai, L.; Zhang, J.; Chen, Y.; Mackenzie, L. E.; Pal, R.; Law, G. L. Synthesis of Water-Soluble Chiral DOTA 
Lanthanide Complexes with Predominantly Twisted Square Antiprism Isomers and Circularly Polarized 
Luminescence (Supplementary material). Inorg. Chem. 2019, 58 (19), 12506-12510. 
[24] Zur, A. A.; Chien, H. C.; Augustyn, E.; Flint, A.; Heeren, N.; Finke, K.; Hernandez, C.; Hansen, L.; Miller, 
S.; Lin, L.; et al. LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates 
(Supplementary material). Bioorganic Med. Chem. Lett. 2016, 26 (20), 5000-5006. 
[25] Taylor, P.; Nyéki, O.; Rill, A.; Klsfaludy, L. RACEMIZATION-FREE PREPARATION OF Boc-Tyr ( Et ) -OH 
ACTIVE ESTERS. Organic Preparations and Procedures International : The New Journal for Organic 
Synthesis. 2014, 20 (1), 96-99. 
Entry Solvent Reagents Conditions Yield (%) Reference 
1 THF:water (1:1) 
Et3N (1.7 eq) 
Boc2O (1.1 eq) 
20 – 25ºC 
20hrs 
92 
Manik Reddi et 
al.[21] 
2 THF 
NaOH (2.2 eq) 
Boc2O (1.1 eq) 
20 – 25ºC 
8-10 hrs 
94 
Yingjie Zhang et 
al. [22] 
3 THF:water (1:2.5) 
NaOH (4.5 M) 
Cbz-Cl (1.2 eq) 
20 – 25ºC 
12 hrs 
95 
Lixiong Dai et al. 
[23] 
4 THF 
NaOH (2.2 M) 
Cbz-Cl (1.2 eq) 
20 – 25ºC 
Overnight 
100 
Arik A. Zur et 
al.[24] 
2a 3a




the crude oil was dissolved in AcOEt and then acidified to reach a pH 1 with 1M aqueous 
solution of HCl. By doing the acidification process on this manner, the measurement of 
the pH of the solution is significantly difficult since the pH medium in organic solvent 
cannot be safely controlled. As a result, low yields are obtained in comparison to entry 
2. For this reason, acidifying the crude oil before dissolved in AcOEt had a remarkable 
increasement in yielding process (entry 2). 
Table 5. Phenol O-Alkylation conditions. 
 
On the other hand, an alternative way for the alkylation process could be using 
ethyl iodide (EtI) instead of diethyl sulphate. We should take into consideration that this 
change in reagent conditions raise the price of the industrial process and the toxicity 
concerns as well. Schmitt-Willich et al[26] performed the resulting alkylation (entry 3, 
Table 5) using a similar subtrate (NR-benzyloxycarbonyl-L-tyrosine methyl ester) at large 
scale, obtaining considerably high yields along with high purities without the need of 
purify the resulting product. Different conditions have been found to take place the 
corresponding phenol alkylation, but in this case the appeal for aqueous conditions as 
mentioned before in entry 2 are the best option in terms of green chemistry.  
3.3. Reduction of Carboxylic Acid 
The following step during the process is the activation of carboxylic acid, as an 
ester or anhydride, to make its reduction to alcohol under mild conditions. There are 
reported several conditions for taking the direct reduction to alcohol from the carboxylic 
acid starting material. For instance, Jan Willimiak Simek et al. [27] in 1997 described an 
alternative procedure, used more in academic labs rather than at level scale that 
 
[26] Schmitt-Willich, H.; Brehm, M.; Ewers, C. L. J.; Michl, G.; Müller-Fahrnow, A.; Petrov, O.; Platzek, J.; 
Radüchel, B.; Sülzle, D. Synthesis and physicochemical characterization of a new gadolinium chelate: The 
liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg. Chem. 1999, 38 (6), 1134-
1144. 
[27] Simek, J. W.; Tuck, T.; Bush, K. C. Reduction of Carboxylic Acids with Sodium Borohydride and an 
Electrophile. Journal of Chemical Education. 1997, 74 (1), 107-108. 
Entry Solvent Reagents Conditions Yield (%) Reference 
1 water 
4M NaOH (3ml/g) 
Et2SO4 (2.0eq) 
20 – 25ºC 
2 – 3 hrs 
78 





20 – 25ºC 
24 hrs 
94 O. Nyéki et al. [25] 
3 DMF 
K2CO3(1.1 eq) 
EtI (1.1 eq) 









implicates the reduction of carboxylic acids with sodium borohydride and an 
electrophile, such as iodine in THF solution.  A clear example in a 40 g scale was done by 
Lixiong Dai et al.[23] using the mentioned reaction with a similar substrate (10) obtaining 
the resulting alcohol (11) in 86% yield (see Table 6 for the conditions). 
Table 6. Reaction conditions of carboxylic reductions in presence of an electrophile. 
This synthetic methodology results in the reduction in one step, so if this strategy 
will consider in the synthesis of Gadoxetate it will shorten the required number of steps. 
However, in previous substrates some by-products were formed during the reaction and 
a rigorous workup is needed to obtain considerably purities making it unsuitable for its 
industrialization. For this reason, plus to the high cost of iodine this procedure is in 
disuse at industrial scale, but it could be tried in further trials using our substrate to 
verify the prior drawbacks. So as mentioned later, it seems that the best choice would 
be activating the carboxylic agent and then take place the subsequent reduction in 
presence of a reductant agent. Two different pathways have been carried out to achieve 
the desired alcohol. The first route reported in patent WO2017208258[21] (see Scheme 
4)  involves the formation of the anhydride intermediate 12, by treating compound 3a 
with ethyl chloroformate (ECF) under N2 atmosphere and in basic medium and followed 
by a suitable reductant agent like sodium borohydride (NaBH4) to obtain (S)-tert-butyl 
(1-(4-ethoxyphenyl)-3-hydroxypropan -2-yl) carbamate(4a).  
Scheme 4. Acid Carboxylic reduction via anhydride and subsequent reduction with NaBH4.a 
 
 
aReagents and conditions: (i) CH2Cl2, NEt3 (6 eq.), ECF (4 eq.), 0-30ºC, >3 hrs (ii) NaBH4 (3.0 eq.), THF, 0ºC 
– r.t 
 
Entry Solvent Reagents Conditions Yield (%) Reference 
1 THF 
NaBH4 (3.5 eq) 
I2 (1.2 eq) 
Reflux at 
70ºC over 16 
hrs 
86 









The overall yield of the synthetic pathway illustrated in Scheme 4 was 60 % using the 
conditions mentioned above. Previous experiments using the same conditions and 
changing different variables, like reaction time and solvents, were carried out in CQAB 
facilities to isolate the compound 4a in good yields. However, these changes in the 
experimental condition did not afford satisfactory results. These outcomes could be 
explained due to the high reactivity of the resulting intermediate 12 leading to its 
decomposition before its reduction. However, much more attempts can be done to 
improve the yielding process of this pathway by changing the base reagent or the 
chloroformate used. In patent WO2019166937, George Griesgraber et al.[28] reported 
the reduction of (2S)-2-(tert-butoxycarbonylamino)-3-(4-tert-butoxyphenyl)propanoic 
acid (13) (see Scheme 5) in presence of N-methylmorpholine as a base and isobutyl 
chloroformate as an electrophile to get the resulting anhydride intermediate 14. Then, 
a subsequent reduction with sodium borohydride reached the desired alcohol 15, as a 
syrup. Finally, the product was isolated by precipitation into vigorously stirred heptane 
to get the desired product as a white solid in a 95% yield.  
Scheme 5. Acid Carboxylic reduction reported in patent WO2019166937.a 
a Reagents and conditions: (i) THF anhydrous, N-methylmorpholine (1.0 eq.), Isobutylchloroformate (1.0 
eq.), -15ºC – r.t (ii) NaBH4 (2.0 eq.) in THF, 0ºC – r.t 
This improvement, in yield terms, it could be explained by the less reactive 
anhydride intermediate 14 generated using a different chloroformate. For future 
experiments, these conditions might be used to test if it is possible to achieve compound 
4a in good yield and purity as well. On the other hand, a second approach to obtain the 
desired alcohol could be accomplished by the generation of an intermediate methyl 
ester 16, followed by its reduction to alcohol as reported in patent WO2017208258[21] 
(see Scheme 6 ).  
 
[28] Griesgraber, G. W.; Substituted imidazo[4,5-c] quinoline compounds with an n-1 branched group. 
WO 2019/166937 A1, Febr 28, 2019. 
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Scheme 6. Acid Carboxylic reduction via methyl ester and subsequent reduction with NaBH4.a 
aReagents and conditions: (i) DMF, K2CO3 (3.0 eq.), MeI (1.5 eq.) (ii) NaBH4 (3.0 eq.), THF, MeOH, 18 hrs, 
0ºC – r.t 
This process seems to be easy handle for industrial manipulation since ester 
intermediate is less reactive than anhydride compound, obtaining the resulting alcohol 
between 70-75 % yield after precipitation in cyclohexane and with high purity (96%). 
Another interesting route for obtaining the alcohol can be carried out directly from L-
protected tyrosine by shortening the number of synthetic steps as it is shown in Table 
7. Lixiong Dai et al. [23] reported a two steps methodology pathway which involves in a 
single step the O-alkylation and the resulting esterification to get compound 17. The 
second step involves a simple reduction of the resulting ester in presence of sodium 
borohydride to obtain 18 with 80 % overall yield. As we introduced in the synthetic 
pathway of Scheme 1, this was carried out in two steps at different conditions to get 
compound 4a in a 60% yield. Even though in the conditions mentioned in Table 7 uses 
methyl iodide instead of ethyl iodide, it is of great interest to try these conditions with 
iodo ethane in order to find out if the synthetic pathway can shorten as well as increase 
the total yield of the process. 









K2CO3 (3.9 eq) 
MeI (2.5 eq) 
20 – 25ºC 
16 hrs 
80 
Lixiong Dai et 
al23 2 
 
Methanol NaBH4 (3.0 eq) 





Step 1 Step 2




Moreover, in patent WO03057722A2[29], Shigeki Satoh and coworkers reported the 
direct phenol alkylation and ethyl esterification of Cbz-L-Tyrosine (2b) (see Scheme 7)  
Scheme 7. Phenol alkylation and esterification of Cbz-L-Tyrosine.a 
 
 
aReagents and conditions: (i) DMF, K2CO3 (3.6 eq.), EtI (3.3 eq.), 0 – 25ºC, 48 hrs 
At this point, the current challenge that we can face is if the reduction conditions 
with NaBH4 mentioned before (Table 7, entry 2) are enough to take the resulting 
reduction of intermediate 19 in good yields or it would be needed different conditions 
which can provoke a change in the reductant agent leading a raise in the production 
cost. This doubt is yet to be determined in future experiments for our substrate, though 
in literature some examples have been described.  Chuanxin Leng et al in-patent CN 
103896788[30] described the exact reduction of compound 19 to get the resulting alcohol 
in presence of NaBH4 as a reducing agent. They performed the reaction in THF solvent 
and 3.0 eq. of sodium borohydride at 25ºC for 3 hrs to get the resulting compound after 
the work-up procedure in a 95.6% yield and with purity of 99.3%.  
3.4. Hydroxyl group activation 
The next synthetic step implicates the activation of alcohol group of compound 
4(a-c) under N2 atmosphere conditions at 0ºC as it is shown in Scheme 8 . Initially in 
patent WO2017208258[21], at large scale, it was carried out using the alcohol 4a 
derivative in order to get the resulting mesylate compound 5a in a 64% yield, by treating 
4a with methanesulfonyl chloride (1.5 eq.) in presence of basic medium such as 
trimethylamine (5 eq.) to provide the desired compound (see  
Table 8, entry 1 for conditions). As we mentioned before, starting the synthesis 
by protecting the amine group in presence of benzyl chloroformate can be an alternative 
to our synthetic approach. One clear advantage in terms of stability is the endurance of 
 
[29] Satoh, S.; Urano, Y. Cyclic tetrapeptide compound and use thereof. WO 03/057722 a2.2, Dec 27, 2002. 
[30] CN103896788A - Preparation method of S-1-(4-ethyoxylbenzyl)-3-azapentane-1,5-
diaminetrihydrochloride - Google Patents https://patents.google.com/patent/CN103896788A/en 
(accessed may 11, 2020). 
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the resulting protecting group in acidic medium making it more suitable for all 
conditions throughout the synthetic pathway. Another advantage could be in that 
reaction specifically. Further literature [31] was found regarding the activation of hydroxyl 
groups in similar Cbz-protected tyrosine derivatives substrates which confirm us a better 
yielding process, as one can see in Table 9 (Entries 2&3). 




Table 8. Reaction conditions for the synthesis of mesylate derivatives. 
Entry Comp. R X Solvent Reagents Conditions Yield (%) Reference 
1 5a Boc OEt THF 
1.5 eq. MsCl 
5 eq. NMe3 





2 5b Cbz OEt THF 
1.1 Eq. 
MsCl 
1.1 eq. Net3 






3 5c Cbz OtBu THF 
1.1 Eq. 
MsCl 
3 eq. Net3 





Veitia et al 
[29] 
At last, a crystallization process of compound 5(a-c) can be taken place from a 
mixture water/tetrahydrofuran to get the desired compound with high purity.  
3.5. Nucleophilic Substitution in presence of Ethylenediamine 
The following synthetic step is based on a nucleophilic substitution reaction (SN 2 
type) on mesylate derivative in presence of ethylenediamine (en) as a nucleophilic agent 
to get the resulting triamine-monoprotected derivative 6 (Scheme 9).  




[31] Veitía, M. S. I.; Brun, P. L.; Jorda, P.; Falguières, A.; Ferroud, C. Synthesis of novel N-protected β3-
amino nitriles: study of their hydrolysis involving a nitrilase-catalyzed step. Tetrahedron Asymmetry 2009, 









The reaction conditions depend on the substrate 5(a-b), which containing Boc or Cbz as 
a protecting group. Results shown below (Table 9), indicate that better results are 
achieved in yielding terms using Benzyl N-[S-1-(4-Ethoxybenzyl)-2-
mesyloxyethyl]carbamate (5b), after its crystallization in methanol : MTBE. Then, the 
resulting solid was acidified in presence of HCl to form the salt 6b which was isolated 
after washing with MTBE and drying at 50ºC.  
Table 9. Reaction conditions for the amine condensation. 
Entry Compound R Solvent Reagents Conditions Yield (%) Reference 
1 6a Boc THF 25 eq. en 
20 – 65ºC 
10 – 12hrs 
72 
Manik Reddi et 
al[21] 






3.6. Deprotection groups conditions 
At this point, two different conditions can be used for deprotecting the amine 
protecting groups depending on the substrate used. Firstly, as it is shown in the total 
pathway of Scheme 1, Boc’s deprotection was carried out under acidic conditions (2M 
HCl) in dioxane to get the resulting triamine hydrochloride (7) in a 68% yield. Many 
conditions were found in literature to take this process with a suitable yield in a large 
variety of substrates. However, better yields in this step can be achieved by using 
different conditions as we mention below. Yeong Hun et al [32] in patent WO2018084625 
reported a better condition for the Boc’s deprotection obtaining high yields in 
comparison to conditions mentioned before. They treated the compound 6a with a 
mixture of MeOH and acetyl chloride at 50ºC for 1hour (see Table 10, entry 2) to get the 
resulting triamine trihydrochloride with a 99% yield, after its crystallization with MTBE. 
These outcomes might be useful for our interests to enhance the efficiency of the Boc’s 
protection process. In case of preserving the same synthetic protecting group (Boc) it 
could be beneficial to test the deprotection conditions as entry 2 to improve 
considerably the process´s yield 
 
[32] Bureau, I.; Hun, Y.; Woo, H.; Jin, H.; Kyu, S.; Ki, S.; Jho, G.; States, D. METHOD FOR PREPARATION OF 
(S)-Nl-(2-AMINOETHYL)-3-(4-ALKOXYPHENYL)PROPANE-l,2 -DIAMINE TRIHYDROCHLORIDE. WO Patent 
2018/084625 A1, May 11, 2018. 
 




By contrast, using Cbz as a protecting group provide us orthogonal conditions for 
its cleavage. The combination of hydrogen and a Pd/C catalyst has proved to be the most 
effective system. Two different conditions were found using Palladium catalyst which its 
conditions are shown in (Table 10, entries 3 and 4). First of all, Schmitt Willich et al.[26] 
reported exactly the Cbz deprotection using the same substrate 6b for the synthesis of 
Gadoxetate by doing the hydrogenolysis over 10% Pd on charcoal at 15 bar for 1h at 
room temperature (see entry 3), obtaining the desired product 7 with 92.5 % yield after 
its crystallization from a mixture of methanol : MTBE (1:4). On the other hand, Lixiong 
et al. [23] reported the Cbz removal conditions in another substrate using the same 
amount of catalyst but differing in the pressure applied to the system. In this case, only 
1 atmosphere of hydrogen was used obtaining the unprotected product after 16 hours 
with yield of 100%. Overall, similar results are achieved on the respective deprotection 
of Cbz group allowing us to choose the pressure value adequate to our needs.  
Table 10. Reaction conditions for Boc and Cbz deprotection in 6a or 6b. 
 
3.7. Synthesis of Ethoxy Benzyl Diethylenetriamine Pentaacetic Acid  
The penultimate step of this multi-lineal synthesis consists on the alkylation of 
triamine salt 7 in presence of a base along with an electrophilic agent to get the resulting 
triazaundecandioic acid 8. Many synthetic approaches have been done to produce 
compound 8 as it is shown in Scheme 10, 11 & 12. 
 
Entry Substrate Solvent Reagents Conditions Yield (%) Reference 
1 6a Dioxane HCl 3M 
20 – 25ºC 








Yeong Hun et 
al[32] 
3 6b MeOH 
10% Pd on 
charcoal 




Willich et al[26] 
4 6b EtOH 
10% Pd on 
charcoal 
r.t, 1 atm H2, 16 
hrs 
100 








Schmitt-Willich et al[26] reported the synthesis of compound 8 from compound 7 in two 
steps as it is shown in Scheme 10 . The first step involves the alkylation of triamine salt 
7 with tert-butyl bromoacetate in presence of potassium carbonate (K2CO3), as a base, 
to obtain the tertbutyl ester intermediate 7a, in a 73% yield after column 
chromatography. Whereas, the second step implicates the subsequent hydrolysis of 
intermediate 7a in basic conditions, followed by acidification process using the cation 
exchange column chromatography resin Amberlite IR 120 (H+ form). By using this 
strategy, the compound 8 was isolated in 94% yield.  
Scheme 10. Synthetic pathway toward compound 8 by Schmitt-Willich and coworkers.a 
aReagents and conditions: (i) BrCH2COOtBu, THF/H2O, K2CO3, 20h, reflux; chromatography (ii) aqueous 
NaOH/methanol, 5h reflux, overnight r.t, IR 120 (H+) to pH 3. 
One drawback of this methodology is that after the alkylation process, an 
expensive chromatographic step is required to purify the intermediate 7a from 
unreacted bromoacetic acid tert-butyl ester. On the other hand, after the saponification 
of tert-butyl ester, the residue must be passed through an ion exchange acidic column 
chromatography which becomes expensive for industrial sectors. As well, in patent of 
Scheme 1, the inventors also use the treatment of a strong acidic resin like INDION 225H.  
For this reason, there is a need to avoid this expensive purification and try to use 
different conditions or different reagents to find out a better suitable and easy-handle 
procedure for the industrial production. In another patent CN104130146A[33] is reported 
an alternative method for the synthesis of ethoxy benzyl diethylenetriamine penta 
acetic acid part (EOB- DTPA) which compromised two steps as well, as it is shown in 
Scheme 11.  
 
[33] CN104130146A - Preparation method of (4S)-3, 6, 9-triaza-3, 6, 9-tri(carboxymethyl)-4-(4-ethoxy 
benzyl)undecanedioic acid - Google Patents https://patents.google.com/patent/CN104130146A/en 
(accessed may 6, 2020). 
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aReagents and conditions: (i) Chloracetonitrile (7.5 eq.), Na2CO3 (8.0 eq.), THF : water, 80ºC, reflux, 5-8 hrs 
(60% yield) (ii) KOH (25.0 eq.), Methanol:water (30:1), reflux 20-30 hrs. 
The first step consists on the amine alkylation using chloroacetonitrile as an 
electrophilic agent and sodium carbonate as a base in a mixture of THF:water, which 
react under reflux between 5-8 hrs to get compound 7b in a 60 % yield after 
recrystallization with ethyl acetate. Next, the resulting penta nitrile compound is 
hydrolysed in basic solution of potassium hydroxide between 20-30 hrs at reflux. Then, 
the solution was concentrated, dissolved in water, and acidified with 2N aqueous 
sulfuric acid solution to reach a pH around 1.5. Under these conditions, the compound 
8 is precipitated, filtered, washed, and recrystallized in hot water. After that, the 
compound 8 was isolated in a 66% yield. Compared with Schmitt[26] methodology, these 
conditions have the following advantages of avoiding chromatographic purification in 
the first step, owing to a changing in the electrophilic agent from halo-acetic acid tert-
butyl to halo-acetonitrile, which then intermediate 7b can adopt a recrystallization 
process that results in a simple way of purification. Finally, the compound 8 is obtained 
without the appealing of an ion exchange resin column chromatography where in some 
cases are beneficial in economic terms. In general, that synthetic route is brief, easy, and 
simple to handle and the most important thing as always is the easy cost.  Unfortunately, 
this technique among the advantages that it has, it has been in disuse due to the toxicity  
concerns of halo-acetonitrile reagent as well as its cost.  
However, in patent DE102010023890A1[34] is reported the obtention of crystalline form 
of ligand EOB-DTPA from intermediate 7a tert-butyl ester. They used similar conditions 
in the saponification process like mentioned before (CN104130146A[33]) to obtain 
 
[34] DE102010023890A1 - Preparing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(ethoxybenzyl)-
undecanedioic acid comprises hydrolyzing 3,6,9-triaza-3,6,9-tris(tert-butoxy-carbonylmethyl)-4-
(ethoxybenzyl)-undecanedioic acid-ditert-butylester and acidifying - Google Patents 
https://patents.google.com/patent/DE102010023890A1/en (accessed may 7, 2020). 




compound 8 in a high purity and in crystalline form saving at the same time the use of 
an ion exchange treatment. At last, there is an alternative way reported in patent 
CN104761461A [35] which shorten the reaction steps for the obtention of the ligand EOB-
DTPA. As one can see illustrated in Scheme 12, it is based on the direct alkylation of 
chiral triamine salt (7) in presence of sodium hydroxide and a halo acetic compound, 
which can be sodium chloro- or bromoacetate.  
Scheme 12. Synthesis of ligand EOB-DTPA in a single step.a  
 
 
aReagents and conditions: (i) NaOCOCH2X (X: Cl, Br), NaOH, Reflux 20-40 hrs. 
In practical terms (see Table 12  for the conditions), compound 7 is solubilized in 
water, then between 5 – 12 eq. of sodium hydroxide is added along with sodium chloro- 
or bromo acetate (6 – 10 eq.) and the mixture is left rising reflux temperature around 
20 – 30 hrs. After the reaction is completed, the residue is acidified with concentrated 
sulphuric or hydrochloric acid to pH 2-3. The resulting precipitated is filtered out and 
dried, obtaining better yields (73 – 77%) in comparison to Scheme 1 (42%) as well as 
with high purities (98 – 99%). The obtained solid might carried out further purification 
steps by water recrystallization or from a mixture of protic solvents like methanol and 
isopropyl alcohol.  
This procedure presents better advantages from others. For example, the 
reaction conditions are environmental friendliness since does not adopt organic solvent 
and produce organic by-products. Moreover, the contaminants generated are few and 
the product purity is high. Finally, the raw material is easy to get which means in a lower 




[35] CN104761461A - Preparation method of novel gadoxetate disodium intermediate - Google Patents 








Table 12. Reaction conditions for the obtention of EOB-DTPA ligand.[35] 
 
3.8. Gadoxetate Disodium complex formation 
The last step of the synthetic pathway involves the complexation of crystalline  
ligand EOB-DTPA obtained in previous step in presence of gadolinium oxide (Gd2O3) as 
it is shown in Scheme 13. 






aReagents and conditions: (i) Gd2O3, 1-5 hrs, 80ºC, aqueous NaOH to pH 7, recrystallized from ethanol/H2O 
 
The complexation of compound 8 was performed with 0.5 eq. of gadolinium 
oxide (Gd2O3) in water at 80ºC to give the desired compound 9 between 1-5 hrs after its 
neutralization to pH 7 with 1M NaOH solution. Next, was treated activated carbon at 40-
45ºC to remove undesired impurities and filtered through hyflo bed.  The resulting 
solution can be recrystallized at 50ºC over 2 hours from a mixture of ethanol/water 
(95:5). After cooling at room temperature, the subsequent precipitation was observed 
to get Gadoxetate disodium 9 as a white powder after its drying under vacuum. Finally, 
the final compound was isolated with 85% yield and with high purity (>98%). Elemental 
analysis indicated that the gadolinium complex isolated at pH 7.0 has 1.75 sodium ions 
per molecule, obtaining the desired complex salt.  
Anal. Calcd (found) for C23H28GdN3Na1.75O11: C, 38.36 (38.27); H, 3.95 (3.70); Gd, 21.83 
(21.08); N, 5.83 (5.78); Na, 5.59 (5.50).
Entry Solvent Reagents Conditions Yield (%) Purity 
1 Water 
NaOH (5.9 eq.) 
NaOCOCH2Cl (6 eq.) 
Reflux 30 hrs 75.1 98.2 % 
2 Water 
NaOH (11.9 eq.) 
NaOCOCH2Br (7 eq.) 
Reflux 20 hrs 73.8 98 % 
3 Water 
NaOH (11.9 eq.) 
NaOCOCH2Cl (10 eq.) 










Based on the recent synthetic pathway of Scheme 1 at large scale reported in 
patent WO2017208258A1 along with an exhaustive bibliographic search, it has been 
proposed an alternative route:  
• Firstly, it was removed the Boc protecting group by replacing it to Cbz group, 
which provide a better endurance for the conditions required throughout the 
synthetic route.  
• Secondly, in the second step which involves the O-alkylation of compound 2a, it 
was found that in presence of ethyl iodide and K2CO3 a direct O-alkylation along 
with the resulting ester formation could be carried out allowing us to shorten the 
synthetic steps of the process. Furthermore, further trials should be carried out 
to test if by increasing the equivalents of Et2SO4 similar outcomes could be 
achieved.  
• On the other hand, a better improvement in the reproducibility and cost of the 
process was achieved by obtaining the resulting ligand EOB-DTPA after its 
acidification using an inorganic acid aqueous solution, instead of the appealing 
of an ion exchange resin column chromatography which increase the cost as well 
as the system design of the process.  
• Finally, the Scheme 14 provide a viable synthetic route towards Gadoxetate, 
which possess some special and appealing features like low cost, easy and simple 
to handle and the most essential thing, the great suitability for its 
industrialization obtaining the resulting compound with theorical better yield 




































c) HCl, 3 M
4b
e) MsCl (1.1 eq.)
    NEt3 (1.1 eq.) 
THF 
50 ºC, 4 hrs
8
h) ClCH2CO2Na (10.0 eq.)
    NaOH (11.9 eq.), H2O
f)  Ethylendiamine (25.0 eq.), THF, 
                       HCl  
THF, 0 - r.t., 30 min
d)  NaBH4 (3.0 eq.), THF,
   , 0ºC - r.t,  3 hrs
9
a) NaOH (2.2M), 




b) K2CO3 (3.6 eq.), EtI (3.3 eq.)
pH 2 - 3, inorganic acid (sulphuric acid ) 
1





g) 10% Pd on charcoal,




    
Yield: 77%
aqueous NaOH to pH 7
Yield: 81 %
